Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)
SEK 51.6
(-7.53%)
SEK 51.6
(-7.53%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 46.18 Million SEK | 157.8% |
| 2022 | 17.91 Million SEK | 35.46% |
| 2021 | 13.22 Million SEK | 30.11% |
| 2020 | 10.16 Million SEK | 29.05% |
| 2019 | 7.87 Million SEK | 18.36% |
| 2018 | 6.65 Million SEK | 0.02% |
| 2017 | 6.65 Million SEK | 36.25% |
| 2016 | 4.88 Million SEK | -36.86% |
| 2015 | 7.73 Million SEK | 120.59% |
| 2014 | 3.5 Million SEK | 1356.61% |
| 2013 | 240.69 Thousand SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 71.53 Million SEK | 54.91% |
| 2024 Q2 | 59.76 Million SEK | -16.45% |
| 2023 Q3 | 40.66 Million SEK | 11.54% |
| 2023 FY | 46.18 Million SEK | 157.8% |
| 2023 Q4 | 46.18 Million SEK | 13.55% |
| 2023 Q1 | 24.45 Million SEK | 36.53% |
| 2023 Q2 | 36.46 Million SEK | 49.09% |
| 2022 Q1 | 33.91 Million SEK | 156.46% |
| 2022 Q2 | 20.4 Million SEK | -39.84% |
| 2022 Q4 | 17.91 Million SEK | -27.0% |
| 2022 Q3 | 24.53 Million SEK | 20.28% |
| 2022 FY | 17.91 Million SEK | 35.46% |
| 2021 Q4 | 13.22 Million SEK | 32.51% |
| 2021 Q1 | 10.44 Million SEK | 2.77% |
| 2021 Q2 | 17.88 Million SEK | 71.22% |
| 2021 FY | 13.22 Million SEK | 30.11% |
| 2021 Q3 | 9.98 Million SEK | -44.2% |
| 2020 Q1 | 11.59 Million SEK | 47.19% |
| 2020 FY | 10.16 Million SEK | 29.05% |
| 2020 Q2 | 8.96 Million SEK | -22.67% |
| 2020 Q3 | 15.24 Million SEK | 70.09% |
| 2020 Q4 | 10.16 Million SEK | -33.35% |
| 2019 Q3 | 7.41 Million SEK | 13.98% |
| 2019 FY | 7.87 Million SEK | 18.36% |
| 2019 Q4 | 7.87 Million SEK | 6.19% |
| 2019 Q2 | 6.5 Million SEK | 30.01% |
| 2019 Q1 | 5 Million SEK | -24.78% |
| 2018 FY | 6.65 Million SEK | 0.02% |
| 2018 Q2 | 10.6 Million SEK | 29.92% |
| 2018 Q4 | 6.65 Million SEK | -25.74% |
| 2018 Q3 | 8.96 Million SEK | -15.5% |
| 2018 Q1 | 8.16 Million SEK | 22.67% |
| 2017 Q3 | 3.99 Million SEK | -53.7% |
| 2017 FY | 6.65 Million SEK | 36.25% |
| 2017 Q1 | 4.26 Million SEK | -12.72% |
| 2017 Q2 | 8.62 Million SEK | 102.37% |
| 2017 Q4 | 6.65 Million SEK | 66.62% |
| 2016 Q4 | 4.88 Million SEK | 0.0% |
| 2016 FY | 4.88 Million SEK | -36.86% |
| 2016 Q2 | 6.07 Million SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2015 Q3 | 7.73 Million SEK | 0.0% |
| 2015 FY | 7.73 Million SEK | 120.59% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q4 | 7.73 Million SEK | 0.0% |
| 2014 FY | 3.5 Million SEK | 1356.61% |
| 2013 FY | 240.69 Thousand SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alzinova AB (publ) | 9.33 Million SEK | -394.909% |
| Amniotics AB (publ) | 10.54 Million SEK | -337.85% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -943.38% |
| BioArctic AB (publ) | 139.5 Million SEK | 66.897% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 97.051% |
| Genovis AB (publ.) | 98.04 Million SEK | 52.9% |
| LIDDS AB (publ) | 3.75 Million SEK | -1129.499% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 62.752% |
| OncoZenge AB (publ) | 1.69 Million SEK | -2618.069% |
| Saniona AB (publ) | 86.08 Million SEK | 46.354% |
| Simris Alg AB (publ) | 148.93 Million SEK | 68.994% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -13.023% |
| AcouSort AB (publ) | 10.37 Million SEK | -344.98% |
| Active Biotech AB (publ) | 13.4 Million SEK | -244.627% |
| Camurus AB (publ) | 414.81 Million SEK | 88.867% |
| Cantargia AB (publ) | 54.97 Million SEK | 15.991% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -1103.231% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -149.703% |
| Mendus AB (publ) | 51.22 Million SEK | 9.849% |
| Kancera AB (publ) | 17.97 Million SEK | -156.87% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -299.17% |
| Lipum AB (publ) | 7.53 Million SEK | -512.629% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -795.308% |
| NextCell Pharma AB | 13.68 Million SEK | -237.35% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 90.423% |
| Xintela AB (publ) | 14.01 Million SEK | -229.504% |
| Ziccum AB (publ) | 6.38 Million SEK | -622.918% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -235.328% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -1857.609% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -140.973% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 35.727% |
| CombiGene AB (publ) | 4.15 Million SEK | -1011.165% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 35.066% |
| Intervacc AB (publ) | 21.68 Million SEK | -113.007% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 56.677% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -33.457% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -72.907% |
| Corline Biomedical AB | 6.78 Million SEK | -580.218% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 24.736% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -186.53% |
| Aptahem AB (publ) | 8.99 Million SEK | -413.235% |
| Fluicell AB (publ) | 8.91 Million SEK | -418.003% |
| Biovica International AB (publ) | 34.76 Million SEK | -32.827% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -295.783% |
| Abliva AB (publ) | 16.78 Million SEK | -175.192% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 78.481% |
| 2cureX AB (publ) | 2.93 Million SEK | -1473.424% |
| I-Tech AB | 16.2 Million SEK | -184.974% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 96.106% |
| Cyxone AB (publ) | 4.69 Million SEK | -883.809% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -246.489% |
| Biosergen AB | 5.08 Million SEK | -808.161% |
| Nanologica AB (publ) | 79.32 Million SEK | 41.785% |
| SynAct Pharma AB | 51.83 Million SEK | 10.908% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -480.954% |
| BioInvent International AB (publ) | 90.45 Million SEK | 48.946% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -788.941% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 74.57% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -2474.136% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -262.367% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -536.088% |